Silence Net Income From Continuing Ops vs Cost Of Revenue Analysis

SLN Stock

USD 6.60 0.15 2.33%

Silence Therapeutics financial indicator trend analysis is much more than just breaking down Silence Therapeutics PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Silence Therapeutics PLC is a good investment. Please check the relationship between Silence Therapeutics Net Income From Continuing Ops and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Silence Therapeutics PLC Net Income From Continuing Ops account and Cost Of Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Silence Therapeutics' Net Income From Continuing Ops and Cost Of Revenue is -0.64. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Silence Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Silence Therapeutics' Net Income From Continuing Ops and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Silence Therapeutics PLC are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income From Continuing Ops i.e., Silence Therapeutics' Net Income From Continuing Ops and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.64

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Net Income From Continuing Ops

Cost Of Revenue

Cost of Revenue is found on Silence Therapeutics PLC income statement and represents the costs associated with goods and services Silence Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Silence Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Silence Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Silence Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 13th of December 2024, Enterprise Value is likely to grow to about 475.5 M, though Tax Provision is likely to grow to (6.7 M).

	2021	2022	2023	2024 (projected)
Interest Expense	8K	47K	34K	32.3K
Depreciation And Amortization	427K	482K	498K	274.8K

Interest Expense Depreciation And Amortization

Silence Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Receivables	Good Will	Inventory	Intangible Assets	Current Deferred Revenue
Total Assets		0.6	0.86	-0.07	0.95	-0.86	-0.92	0.32	0.87	0.12	-0.35	0.92	0.68	0.89	0.89	0.68	0.86	0.89	0.88	0.98	0.79	0.81	-0.14	-0.66	-0.4	0.69
Other Current Liab	0.6		0.79	-0.4	0.43	-0.3	-0.63	0.15	0.33	-0.02	-0.1	0.35	0.45	0.6	0.67	0.72	0.48	0.7	0.44	0.6	0.49	0.88	-0.13	-0.32	-0.24	0.78
Total Current Liabilities	0.86	0.79		-0.48	0.72	-0.54	-0.85	0.35	0.55	-0.01	-0.32	0.67	0.52	0.75	0.93	0.68	0.65	0.96	0.73	0.86	0.63	0.95	-0.16	-0.55	-0.23	0.87
Total Stockholder Equity	-0.07	-0.4	-0.48		0.05	-0.16	0.21	-0.1	0.15	0.25	0.18	0.09	0.17	0.03	-0.51	-0.26	0.16	-0.51	-0.25	-0.11	0.06	-0.39	0.08	0.07	-0.35	-0.29
Property Plant And Equipment Net	0.95	0.43	0.72	0.05		-0.92	-0.88	0.3	0.93	0.04	-0.31	0.95	0.58	0.9	0.81	0.64	0.87	0.8	0.9	0.95	0.7	0.67	-0.25	-0.7	-0.43	0.54
Net Debt	-0.86	-0.3	-0.54	-0.16	-0.92		0.75	-0.21	-1.0	0.04	0.34	-0.96	-0.46	-0.8	-0.7	-0.51	-0.78	-0.67	-0.83	-0.88	-0.56	-0.48	0.32	0.54	0.51	-0.37
Retained Earnings	-0.92	-0.63	-0.85	0.21	-0.88	0.75		-0.4	-0.77	-0.04	0.12	-0.83	-0.63	-0.93	-0.89	-0.81	-0.92	-0.89	-0.91	-0.91	-0.78	-0.78	0.23	0.79	0.37	-0.57
Accounts Payable	0.32	0.15	0.35	-0.1	0.3	-0.21	-0.4		0.2	0.0	0.46	0.39	0.36	0.49	0.3	-0.02	0.44	0.31	0.22	0.33	0.32	0.12	-0.14	0.02	-0.51	0.17
Cash	0.87	0.33	0.55	0.15	0.93	-1.0	-0.77	0.2		-0.04	-0.33	0.96	0.47	0.81	0.71	0.54	0.8	0.68	0.85	0.89	0.58	0.5	-0.32	-0.57	-0.49	0.37
Non Current Assets Total	0.12	-0.02	-0.01	0.25	0.04	0.04	-0.04	0.0	-0.04		-0.14	-0.07	0.72	-0.07	-0.01	-0.01	0.1	-0.01	0.02	-0.06	0.61	-0.01	0.9	-0.05	0.31	-0.02
Non Currrent Assets Other	-0.35	-0.1	-0.32	0.18	-0.31	0.34	0.12	0.46	-0.33	-0.14		-0.26	-0.06	0.01	-0.39	-0.04	0.05	-0.38	-0.3	-0.33	-0.11	-0.36	-0.13	0.09	-0.15	-0.43
Cash And Short Term Investments	0.92	0.35	0.67	0.09	0.95	-0.96	-0.83	0.39	0.96	-0.07	-0.26		0.5	0.88	0.76	0.5	0.84	0.75	0.84	0.94	0.61	0.57	-0.36	-0.56	-0.57	0.48
Common Stock Total Equity	0.68	0.45	0.52	0.17	0.58	-0.46	-0.63	0.36	0.47	0.72	-0.06	0.5		0.59	0.51	0.47	0.68	0.51	0.52	0.55	0.96	0.48	0.51	-0.42	-0.15	0.38
Common Stock Shares Outstanding	0.89	0.6	0.75	0.03	0.9	-0.8	-0.93	0.49	0.81	-0.07	0.01	0.88	0.59		0.75	0.71	0.96	0.76	0.8	0.91	0.69	0.7	-0.38	-0.66	-0.63	0.56
Non Current Liabilities Total	0.89	0.67	0.93	-0.51	0.81	-0.7	-0.89	0.3	0.71	-0.01	-0.39	0.76	0.51	0.75		0.71	0.67	1.0	0.9	0.89	0.65	0.83	-0.16	-0.61	-0.17	0.67
Other Current Assets	0.68	0.72	0.68	-0.26	0.64	-0.51	-0.81	-0.02	0.54	-0.01	-0.04	0.5	0.47	0.71	0.71		0.7	0.72	0.77	0.67	0.64	0.75	-0.14	-0.85	-0.02	0.43
Other Stockholder Equity	0.86	0.48	0.65	0.16	0.87	-0.78	-0.92	0.44	0.8	0.1	0.05	0.84	0.68	0.96	0.67	0.7		0.67	0.79	0.84	0.78	0.6	-0.24	-0.73	-0.55	0.42
Total Liab	0.89	0.7	0.96	-0.51	0.8	-0.67	-0.89	0.31	0.68	-0.01	-0.38	0.75	0.51	0.76	1.0	0.72	0.67		0.87	0.9	0.66	0.87	-0.16	-0.61	-0.18	0.72
Property Plant And Equipment Gross	0.88	0.44	0.73	-0.25	0.9	-0.83	-0.91	0.22	0.85	0.02	-0.3	0.84	0.52	0.8	0.9	0.77	0.79	0.87		0.87	0.7	0.65	-0.18	-0.81	-0.16	0.39
Total Current Assets	0.98	0.6	0.86	-0.11	0.95	-0.88	-0.91	0.33	0.89	-0.06	-0.33	0.94	0.55	0.91	0.89	0.67	0.84	0.9	0.87		0.67	0.81	-0.32	-0.64	-0.47	0.71
Common Stock	0.79	0.49	0.63	0.06	0.7	-0.56	-0.78	0.32	0.58	0.61	-0.11	0.61	0.96	0.69	0.65	0.64	0.78	0.66	0.7	0.67		0.59	0.39	-0.64	-0.1	0.42
Net Receivables	0.81	0.88	0.95	-0.39	0.67	-0.48	-0.78	0.12	0.5	-0.01	-0.36	0.57	0.48	0.7	0.83	0.75	0.6	0.87	0.65	0.81	0.59		-0.15	-0.56	-0.2	0.91
Good Will	-0.14	-0.13	-0.16	0.08	-0.25	0.32	0.23	-0.14	-0.32	0.9	-0.13	-0.36	0.51	-0.38	-0.16	-0.14	-0.24	-0.16	-0.18	-0.32	0.39	-0.15		0.12	0.59	-0.16
Inventory	-0.66	-0.32	-0.55	0.07	-0.7	0.54	0.79	0.02	-0.57	-0.05	0.09	-0.56	-0.42	-0.66	-0.61	-0.85	-0.73	-0.61	-0.81	-0.64	-0.64	-0.56	0.12		-0.05	-0.25
Intangible Assets	-0.4	-0.24	-0.23	-0.35	-0.43	0.51	0.37	-0.51	-0.49	0.31	-0.15	-0.57	-0.15	-0.63	-0.17	-0.02	-0.55	-0.18	-0.16	-0.47	-0.1	-0.2	0.59	-0.05		-0.31
Current Deferred Revenue	0.69	0.78	0.87	-0.29	0.54	-0.37	-0.57	0.17	0.37	-0.02	-0.43	0.48	0.38	0.56	0.67	0.43	0.42	0.72	0.39	0.71	0.42	0.91	-0.16	-0.25	-0.31

Click cells to compare fundamentals

Silence Therapeutics Account Relationship Matchups

Silence Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.1M	86.0M	96.2M	107.5M	93.8M	98.5M
Other Current Liab	5.1M	21.8M	6.2M	589K	14.0M	14.7M
Total Current Liabilities	9.7M	25.6M	15.2M	21.9M	17.8M	18.7M
Total Stockholder Equity	20.9M	9.1M	8.5M	22.1M	17.1M	20.8M
Property Plant And Equipment Net	611K	1.1M	1.9M	2.2M	1.8M	1.9M
Net Debt	(13.2M)	(27.1M)	(73.4M)	(54.4M)	(53.8M)	(51.1M)
Retained Earnings	(152.0M)	(184.2M)	(223.0M)	(263.3M)	(304.6M)	(289.4M)
Accounts Payable	6.9M	2.3M	4.1M	3.2M	2.6M	1.7M
Cash	13.5M	27.4M	73.5M	54.8M	54.0M	56.7M
Non Current Assets Total	8.6M	9.6M	9.9M	10.8M	12.8M	8.2M
Non Currrent Assets Other	20.0M	(9.6M)	(9.9M)	(10.8M)	2.6M	2.7M
Cash And Short Term Investments	33.5M	37.4M	73.5M	71.1M	54.0M	56.7M
Common Stock Total Equity	3.5M	3.6M	3.9M	4.2M	4.8M	5.0M
Common Stock Shares Outstanding	25.0M	27.3M	29.7M	32.2M	37.1M	38.9M
Liabilities And Stockholders Equity	46.1M	86.0M	96.2M	107.5M	93.8M	98.5M
Non Current Liabilities Total	15.5M	51.3M	72.5M	63.5M	59.0M	62.0M
Other Current Assets	885K	9.6M	4.3M	8.2M	26.8M	28.1M
Other Stockholder Equity	171.9M	153.7M	184.3M	226.7M	251.4M	264.0M
Total Liab	25.2M	76.9M	87.7M	85.4M	76.8M	80.6M
Property Plant And Equipment Gross	611K	1.1M	5.5M	5.5M	5.6M	5.8M
Total Current Assets	37.5M	76.4M	86.3M	96.7M	81.0M	85.1M
Common Stock	3.9M	4.2M	4.5M	5.4M	5.9M	6.2M
Accumulated Other Comprehensive Income	169.0M	189.1M	23.8M	24.3M	64.3M	57.1M
Net Receivables	3.1M	29.3M	8.5M	17.3M	18.8M	19.8M
Good Will	7.7M	8.1M	7.6M	8.0M	7.8M	7.8M
Intangible Assets	34K	17K	24K	320K	284K	313.7K
Short Term Investments	319K	5.0M	20.0M	10M	0.0	16.3M
Net Tangible Assets	13.2M	917K	910K	13.7M	12.4M	16.7M
Property Plant Equipment	611K	1.1M	1.9M	2.2M	2.5M	1.5M
Net Invested Capital	20.9M	9.1M	8.5M	22.1M	17.1M	18.9M
Net Working Capital	27.8M	50.8M	71.2M	74.7M	63.3M	56.0M
Capital Stock	3.9M	4.2M	4.5M	5.4M	5.9M	5.0M

Pair Trading with Silence Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Silence Stock

0.9	VALN	Valneva SE ADR	Pair Corr
0.89	ERNA	Eterna Therapeutics	Pair Corr

Moving against Silence Stock

0.84	DYAI	Dyadic International	Pair Corr
0.78	ESPR	Esperion Therapeutics	Pair Corr
0.77	BMY	Bristol Myers Squibb	Pair Corr
0.57	GILD	Gilead Sciences	Pair Corr
0.37	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.

The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Silence Therapeutics PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:

How To Invest In Silence

Details

Is Silence Stock a good investment?

Details

What is Silence Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.76)

Revenue Per Share

0.429

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.22)

Return On Equity

(0.64)

The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Silence Net Income From Continuing Ops vs Cost Of Revenue Analysis

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Cost Of Revenue

Silence Therapeutics fundamental ratios Correlations

Silence Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Silence Therapeutics fundamental ratios Accounts

Pair Trading with Silence Therapeutics

Moving together with Silence Stock

Moving against Silence Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.96	Total Current Liabilities
Cash And Short Term Investments	+ 0.96	Cash
Common Stock	+ 0.96	Common Stock Total Equity
Other Stockholder Equity	+ 0.96	Common Stock Shares Outstanding

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.92	Retained Earnings
Net Debt	- 0.92	Property Plant And Equipment Net
Retained Earnings	- 0.92	Total Assets